Takeda survives Zydus Pharmaceuticals’ appeal of order dismissing US antitrust claims alleging ‘sham’ litigation
Zydus Pharmaceuticals’ antitrust counterclaims against Takeda Pharmaceuticals in a patent case involving the ulcer drug lansoprazole are barred by the Noerr-Pennington doctrine, the US Court of Appeals for the Third Circuit...To view the full article, register now.
Already a subscriber? Click here to view full article